Literature DB >> 17102981

Role of atypical opiates in OCD. Experimental approach through the study of 5-HT(2A/C) receptor-mediated behavior.

M Olga Rojas-Corrales1, Juan Gibert-Rahola, Juan A Mico.   

Abstract

RATIONALE: The selective serotonin (5-HT) reuptake inhibitors (SSRIs) represent the first-line pharmacotherapy for obsessive-compulsive disorder (OCD), and atypical antipsychotic drugs, which block 5-HT2A receptors, are used in augmentation strategies. Opiate drugs are also effective in treatment-refractory OCD and Tourette syndrome. The 5-HT2A-related behavior (i.e., head twitch) has been related with tics, stereotypes, and compulsive symptoms observed in Tourette syndrome and OCD.
OBJECTIVES: The aim of this study was to explore whether 5-HT2A-related behavior is affected by atypical opiate drugs.
MATERIALS AND METHODS: Head-twitch response was induced in mice by administration of either 5-hydroxytryptophan (5-HTP) or the 5-HT2A/C agonist (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI). Dose-effect curves of atypical opiate drugs [(+/-)-tramadol, (-)-methadone and levorphanol], morphine, and other psychoactive drugs (fluvoxamine, desipramine, nefazodone, and clozapine) were performed. Opioid mechanisms were investigated by administration of naloxone.
RESULTS: All the opiates tested reduced both 5-HTP and DOI-induced behavior in a naloxone-reversible fashion, atypical opiates being more effective. The effects of the other drugs depended on the protocol, clozapine being the most effective.
CONCLUSIONS: Combined 5-HT and opioid properties result in a greater efficacy in antagonizing 5-HT2A-related behavior. These results provide behavioral evidence to support convergent effects of the 5-HT and opioid systems in discrete brain areas, offering the potential for therapeutic advances in the management of refractory stereotypes and compulsive behaviors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102981     DOI: 10.1007/s00213-006-0619-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  74 in total

Review 1.  The neurobiology of repetitive behaviors: clues to the neurobiology of Tourette syndrome.

Authors:  A M Graybiel; J J Canales
Journal:  Adv Neurol       Date:  2001

2.  Pharmacological characterization of ear-scratch response in mice as a behavioral model for selective 5-HT2-receptor agonists and evidence for 5-HT1B- and 5-HT2-receptor interactions.

Authors:  N A Darmani; B R Martin; U Pandey; R A Glennon
Journal:  Pharmacol Biochem Behav       Date:  1990-09       Impact factor: 3.533

3.  Sequential use of opioid antagonists and agonists in Tourette's syndrome.

Authors:  B J McConville; A B Norman; M H Fogelson; G Erenberg
Journal:  Lancet       Date:  1994-03-05       Impact factor: 79.321

4.  Quetiapine augmentation in patients with treatment resistant obsessive-compulsive disorder: a single-blind, placebo-controlled study.

Authors:  M Atmaca; M Kuloglu; E Tezcan; O Gecici
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

5.  The pharmacology of impulsive behaviour in rats VI: the effects of ethanol and selective serotonergic drugs on response choice with varying delays of reinforcement.

Authors:  J L Evenden; C N Ryan
Journal:  Psychopharmacology (Berl)       Date:  1999-10       Impact factor: 4.530

6.  Effects of chronic tramadol on pre- and post-synaptic measures of monoamine function.

Authors:  S E Hopwood; C A Owesson; L F Callado; D P McLaughlin; J A Stamford
Journal:  J Psychopharmacol       Date:  2001-09       Impact factor: 4.153

7.  Endogenous opioid activity is associated with obsessive-compulsive symptomology in individuals with a family history of alcoholism.

Authors:  D L Mangold; M Peyrot; P Giggey; G S Wand
Journal:  Neuropsychopharmacology       Date:  2000-06       Impact factor: 7.853

8.  Neuroendocrine and behavioral responses to mCPP in Obsessive-Compulsive Disorder.

Authors:  S Khanna; J P John; L P Reddy
Journal:  Psychoneuroendocrinology       Date:  2001-02       Impact factor: 4.905

9.  Serotonin and norepinephrine uptake inhibiting activity of centrally acting analgesics: structural determinants and role in antinociception.

Authors:  E E Codd; R P Shank; J J Schupsky; R B Raffa
Journal:  J Pharmacol Exp Ther       Date:  1995-09       Impact factor: 4.030

10.  A method for assessing the effects of drugs on the central actions of 5-hydroxytryptamine.

Authors:  S J CORNE; R W PICKERING; B T WARNER
Journal:  Br J Pharmacol Chemother       Date:  1963-02
View more
  10 in total

Review 1.  Head-twitch response in rodents induced by the hallucinogen 2,5-dimethoxy-4-iodoamphetamine: a comprehensive history, a re-evaluation of mechanisms, and its utility as a model.

Authors:  Clint E Canal; Drake Morgan
Journal:  Drug Test Anal       Date:  2012-04-19       Impact factor: 3.345

2.  A novel aminotetralin-type serotonin (5-HT) 2C receptor-specific agonist and 5-HT2A competitive antagonist/5-HT2B inverse agonist with preclinical efficacy for psychoses.

Authors:  Clinton E Canal; Drake Morgan; Daniel Felsing; Krishnakanth Kondabolu; Neil E Rowland; Kimberly L Robertson; Rajeev Sakhuja; Raymond G Booth
Journal:  J Pharmacol Exp Ther       Date:  2014-02-21       Impact factor: 4.030

Review 3.  Obsessive-compulsive disorder, impulse control disorders and drug addiction: common features and potential treatments.

Authors:  Leonardo F Fontenelle; Sanne Oostermeijer; Ben J Harrison; Christos Pantelis; Murat Yücel
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

4.  An evaluation of the serotonin system and perseverative, compulsive, stereotypical, and hyperactive behaviors in dopamine transporter (DAT) knockout mice.

Authors:  Meredith A Fox; Micaella G Panessiti; F Scott Hall; George R Uhl; Dennis L Murphy
Journal:  Psychopharmacology (Berl)       Date:  2013-02-17       Impact factor: 4.530

5.  Tramadol and another atypical opioid meperidine have exaggerated serotonin syndrome behavioural effects, but decreased analgesic effects, in genetically deficient serotonin transporter (SERT) mice.

Authors:  Meredith A Fox; Catherine L Jensen; Dennis L Murphy
Journal:  Int J Neuropsychopharmacol       Date:  2009-03-11       Impact factor: 5.176

Review 6.  Recent advances in the neuropsychopharmacology of serotonergic hallucinogens.

Authors:  Adam L Halberstadt
Journal:  Behav Brain Res       Date:  2014-07-15       Impact factor: 3.332

7.  Buprenorphine augmentation in the treatment of refractory obsessive-compulsive disorder.

Authors:  Malcolm B Liddell; Victor Aziz; Patrick Briggs; Nimalee Kanakkehewa; Omar Rawi
Journal:  Ther Adv Psychopharmacol       Date:  2013-02

8.  Open-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders.

Authors:  Hanik K Yoo; Joong-Sun Lee; Kyoung-Won Paik; Soon-Ho Choi; Sujung J Yoon; Jieun E Kim; Jin Pyo Hong
Journal:  Eur Child Adolesc Psychiatry       Date:  2010-12-28       Impact factor: 4.785

Review 9.  Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD).

Authors:  Antonio Del Casale; Serena Sorice; Alessio Padovano; Maurizio Simmaco; Stefano Ferracuti; Dorian A Lamis; Chiara Rapinesi; Gabriele Sani; Paolo Girardi; Georgios D Kotzalidis; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

10.  Antidepressant-like effects of a water-soluble extract from the culture medium of Ganoderma lucidum mycelia in rats.

Authors:  Hirokazu Matsuzaki; Yuta Shimizu; Naohiro Iwata; Shinya Kamiuchi; Fumiko Suzuki; Hiroshi Iizuka; Yasuhide Hibino; Mari Okazaki
Journal:  BMC Complement Altern Med       Date:  2013-12-26       Impact factor: 3.659

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.